H.C. Wainwright analyst Edward White lowered the firm’s price target on Cullinan Therapeutics to $28 from $29 and keeps a Buy rating on the shares post the Q1 report. The analyst cites higher estimated diluted share count for the target drop.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGEM:
- Cullinan Management Welcomes David Meek to Board of Directors
- Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
- Investor Sentiment Swings in Favor of Cullinan Therapeutics (NASDAQ:CGEM)
- Starbucks downgraded, Dollar Tree upgraded: Wall Street’s top analyst calls
- Cullinan Therapeutics initiated with a Buy at Stifel
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue